Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01469247|
Recruitment Status : Active, not recruiting
First Posted : November 10, 2011
Last Update Posted : May 20, 2019
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy.
You will receive photon radiation therapy. This type of radiation is similar to the radiation you have already had. Conformal radiotherapy or intensity modulated radiotherapy (IMRT) will be used to try to treat the tumor while affecting as little of the surrounding normal tissue as possible.
|Condition or disease||Intervention/treatment||Phase|
|Brain Cancer||Radiation: Radiation Therapy||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma|
|Actual Study Start Date :||December 2011|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2020|
Experimental: Radiation Therapy
Starting dose of 24 Gray (Gy) in 2 Gy fractions.
Radiation: Radiation Therapy
Starting Dose 24 Gy in 2 Gy fractions.
- Optimal Dose Level Among Three Radiation Therapy (RT) Dose Levels [ Time Frame: 1 month after radiation therapy ]Optimal dose level among three RT dose levels, defined in terms of the biologically equivalent dose (BED). The BED is given by the formula BED = (Total Dose)*(1 + d/3), denoting d = dose/fraction, with the constant 3 corresponding to brain tissue.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01469247
|United States, Florida|
|Orlando, Florida, United States, 32806|
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Susan L. McGovern, MD||M.D. Anderson Cancer Center|